Ling V, Kartner N, Sudo T, Siminovitch L, Riordan J R
Cancer Treat Rep. 1983 Oct;67(10):869-74.
Multidrug resistance is a complex pleiotropic phenotype of cross-resistance and collateral sensitivity to unrelated compounds observed in many mammalian cell mutants selected for resistance to single agents. In Chinese hamster ovary cells, colchicine-resistant mutants expressing this phenotype have been characterized extensively. Such mutants arise apparently from a single genetic event, and the basis of this phenotype appears to be localized at the membrane level, resulting in altered drug permeability. Expression of a 170,000-dalton surface glycoprotein (P-glycoprotein) has been identified to correlate with the multidrug-resistance phenotype. Selection of a second mutation in colchicine-resistant mutants, for resistance to phytohemagglutinin, results in an alteration of the carbohydrate moiety in P-glycoprotein and other surface components. This mutation does not noticeably affect the multi-drug-resistance phenotype. The altered permeability of mutant cells to drugs, however, can be modulated by nonionic detergents or metabolic inhibitors. These findings are consistent with a molecular mechanism of multidrug resistance whereby the pleiotropic response of the cell is mediated by an overexpression of a cell-surface protein, the P-glycoprotein.
多药耐药性是在许多为抵抗单一药物而筛选出的哺乳动物细胞突变体中观察到的对不相关化合物的交叉耐药性和附带敏感性的复杂多效性表型。在中国仓鼠卵巢细胞中,表达这种表型的秋水仙碱抗性突变体已被广泛表征。此类突变体显然源于单一遗传事件,且该表型的基础似乎定位于膜水平,导致药物通透性改变。已确定一种170,000道尔顿的表面糖蛋白(P-糖蛋白)的表达与多药耐药性表型相关。在秋水仙碱抗性突变体中选择第二个突变以抵抗植物血凝素,会导致P-糖蛋白和其他表面成分中碳水化合物部分的改变。该突变不会明显影响多药耐药性表型。然而,突变细胞对药物的改变的通透性可被非离子去污剂或代谢抑制剂调节。这些发现与多药耐药性的分子机制一致,即细胞的多效性反应由细胞表面蛋白P-糖蛋白的过表达介导。